New hope for Hard-to-Treat cancers: targeted drug HY05350 enters human trials
NCT ID NCT07083323
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study tests an experimental drug called HY05350 in people with advanced solid tumors that have a protein called MSLN. The goal is to find safe doses and see if the drug can shrink tumors. About 262 adults aged 18 to 75 who have not responded to standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact
Conditions
Explore the condition pages connected to this study.